Table 2.
Response rates, PFS, and OS for all groups with 10 or more patients
| Therapy | N | ORR (%) | VGPR + CRa (%) | Median PFS (months) | Median OS (months) |
|---|---|---|---|---|---|
| Doublet | 42 | 71 | 48 | 18.5 | 84.9 |
| VD | 17 | 65 | 47 | 24 | NR |
| RD | 15 | 67 | 40 | 18.5 | 66.7 |
| TD | 4 | – | – | – | – |
| MP | 3 | – | – | – | – |
| VC | 2 | – | – | – | – |
| CP | 1 | – | – | – | – |
| Triplet/quadruplet | 71 | 85 | 51 | 21 | NR |
| RVD | 34 | 94 | 65 | 36 | NR |
| With maintenance | 21 | – | – | NR | NR |
| Without maintenance | 13 | – | – | 9 | NR |
| VCD | 13 | 69 | 31 | 16.8 | NR |
| VMP | 11 | 81 | 45 | 14 | NR |
| VCDT | 5 | – | – | – | – |
| MPT | 4 | – | – | – | – |
| VTD | 2 | – | – | – | – |
| CTD | 2 | – | – | – | – |
| All patientsb | 117 | 78 | 48 | 18.6 | 113 |
ORR, overall response rate; VGPR + CR, very good partial response + complete remission; PFS, progression‐free survival; OS, overall survival; VD, bortezomib, dexamethasone; RD, lenalidomide, dexamethasone; TD, thalidomide, dexamethasone; MP, melphalan, predisone; VC, bortezomib, cyclophosphamide; CP, cyclophosphamide, prednisone; RVD, lenalidomide, bortezomib, dexamethasone; +/− maintenance with/without maintenance; VCD, bortezomib, cyclophosphamide, dexamethasone; VMP, bortezomib, melphalan, prednisone; VCDT, bortezomib, cyclophosphamide, dexamethasone, thalidomide; MPT, melphalan, prednisone, thalidomide; VTD, bortezomib, thalidomide, dexamethasone; CTD, cyclophosphamide, thalidomide, dexamethasone.
CR unconfirmed.
Includes four patients whose regimens were corticosteroid‐only.